pentosan polysulfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2097 37300-21-3

Description:

MoleculeDescription

Synonyms:

  • elmiron
  • pentosan polysulfate
  • xylan polysulfate
  • xylan sulfate
  • xylofuranan sulfate
  • pentosan polysulfate sodium
A sulfated pentosyl polysaccharide with heparin-like properties.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.30 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 3 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Sept. 26, 1996 FDA JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Maculopathy 1459.87 18.18 225 3424 2037 63483336
Dry age-related macular degeneration 257.19 18.18 37 3612 191 63485182
Retinal pigmentation 141.80 18.18 20 3629 87 63485286
Retinal dystrophy 95.46 18.18 12 3637 15 63485358
Cystitis interstitial 87.69 18.18 20 3629 1588 63483785
Age-related macular degeneration 79.33 18.18 16 3633 707 63484666
Colon dysplasia 65.15 18.18 10 3639 85 63485288
Off label use 63.56 18.18 127 3522 674335 62811038
Macular degeneration 63.43 18.18 30 3619 24346 63461027
Eyelid exfoliation 59.10 18.18 10 3639 164 63485209
Retinal degeneration 37.60 18.18 9 3640 880 63484493
Retinal toxicity 34.38 18.18 9 3640 1266 63484107
Retinopathy 30.41 18.18 10 3639 3109 63482264
Tuberculin test positive 29.25 18.18 10 3639 3501 63481872
Bladder pain 29.10 18.18 9 3640 2299 63483074
Hereditary retinal dystrophy 26.29 18.18 3 3646 0 63485373
Allodynia 23.14 18.18 6 3643 813 63484560
Incorrect dose administered 22.27 18.18 22 3627 59946 63425427
Cholecystitis chronic 21.69 18.18 11 3638 10350 63475023
Retinal drusen 20.92 18.18 3 3646 15 63485358
Neovascular age-related macular degeneration 18.81 18.18 4 3645 229 63485144
Joint contracture 18.73 18.18 6 3643 1718 63483655
Retinal injury 18.63 18.18 4 3645 240 63485133
Retinal pigment epitheliopathy 18.33 18.18 4 3645 259 63485114

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thermophobia 69.51 32.87 9 749 59 34956114
Adrenocorticotropic hormone deficiency 64.56 32.87 12 746 935 34955238
Hypopituitarism 37.93 32.87 9 749 2273 34953900
Anal ulcer 34.34 32.87 7 751 879 34955294
Maculopathy 33.88 32.87 7 751 939 34955234

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Maculopathy 1107.03 19.90 177 3447 2648 79738116
Dry age-related macular degeneration 186.16 19.90 28 3596 267 79740497
Retinal pigmentation 138.74 19.90 19 3605 85 79740679
Cystitis interstitial 101.17 19.90 21 3603 1362 79739402
Age-related macular degeneration 84.25 19.90 17 3607 957 79739807
Macular degeneration 72.74 19.90 25 3599 11271 79729493
Thermophobia 62.81 19.90 9 3615 59 79740705
Eyelid exfoliation 62.80 19.90 10 3614 142 79740622
Retinal dystrophy 59.75 19.90 8 3616 29 79740735
Colon dysplasia 58.84 19.90 10 3614 216 79740548
Adrenocorticotropic hormone deficiency 51.09 19.90 12 3612 1373 79739391
Anal ulcer 45.93 19.90 11 3613 1367 79739397
Off label use 42.89 19.90 113 3511 907102 78833662
Tuberculin test positive 31.85 19.90 10 3614 3398 79737366
Libido decreased 31.25 19.90 11 3613 5310 79735454
Retinal toxicity 30.68 19.90 8 3616 1403 79739361
Hypopituitarism 27.75 19.90 9 3615 3390 79737374
Gonadotrophin deficiency 26.89 19.90 4 3620 35 79740729
Hypogonadism 24.39 19.90 7 3617 1753 79739011
Product use issue 22.81 19.90 37 3587 209785 79530979
Retinal degeneration 21.95 19.90 6 3618 1260 79739504
Cholecystitis chronic 21.47 19.90 10 3614 9896 79730868
Glucocorticoid deficiency 20.63 19.90 5 3619 653 79740111
Allodynia 20.38 19.90 6 3618 1642 79739122

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C05BA04 CARDIOVASCULAR SYSTEM
VASOPROTECTIVES
ANTIVARICOSE THERAPY
Heparins or heparinoids for topical use
ATC G04BX15 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Other urologicals
FDA CS M0009496 Glycosaminoglycans
MeSH PA D000925 Anticoagulants
MeSH PA D006401 Hematologic Agents
FDA EPC N0000175837 Glycosaminoglycan

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bladder pain indication 15803009
Ulcerative cystitis indication 111409009 DOID:13949
Urinary Tract Irritation indication
Gastrointestinal ulcer contraindication 40845000
Blood coagulation disorder contraindication 64779008 DOID:1247
Heparin-induced thrombocytopenia contraindication 73397007
Hemophilia contraindication 90935002
Bleeding contraindication 131148009
Arterial aneurysm contraindication 233981004
Disease of liver contraindication 235856003 DOID:409
Diverticulitis of gastrointestinal tract contraindication 271366000
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Surgical procedure contraindication 387713003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D05428 KEGG_DRUG
140207-93-8 SECONDARY_CAS_RN
4021013 VANDF
C0600296 UMLSCUI
CHEMBL1201516 ChEMBL_ID
D010426 MESH_DESCRIPTOR_UI
DB00686 DRUGBANK_ID
F59P8B75R4 UNII
134413 RXNORM
5255 MMSL
5909 MMSL
80071 MMSL
d04052 MMSL
004395 NDDF
109116008 SNOMEDCT_US
109117004 SNOMEDCT_US
372571007 SNOMEDCT_US
6311 INN_ID
92043424 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ELMIRON HUMAN PRESCRIPTION DRUG LABEL 1 50458-098 CAPSULE, GELATIN COATED 100 mg ORAL NDA 25 sections
ELMIRON HUMAN PRESCRIPTION DRUG LABEL 1 50458-098 CAPSULE, GELATIN COATED 100 mg ORAL NDA 25 sections
Elmiron HUMAN PRESCRIPTION DRUG LABEL 1 54868-4525 CAPSULE, GELATIN COATED 100 mg ORAL NDA 25 sections